Want to see TSE:PRN full AI Analyst Report?
Profound Medical (PRN) AI Stock Analysis
Top Page
Profound Medical
(TSX:PRN)
The score is held back primarily by weak financial quality—deep losses and significant negative free cash flow—despite strong revenue growth and high gross margins. Earnings-call commentary is comparatively constructive (reiterated guidance, improving expense discipline, expanding coverage and pipeline), but technicals remain soft with the stock still below key longer-term moving averages. Valuation provides limited support due to negative earnings and no dividend.
Profound Medical (PRN) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 335.37M
- Dividend Yield
- ―
- Average Volume (3M)
- 14.38K
- Price to Earnings (P/E)
- -6.8
- Beta (1Y)
- 1.67
- Revenue Growth
- 59.60%
- EPS Growth
- 32.53%
- Country
- Canada
- Employees
- 162
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Profound Medical Business Overview & Revenue Model
Company Description
Profound Medical Corp., along with its subsidiaries, operates as a commercial-stage medical technology firm. The company specializes in creating magnetic resonance (MR) guided ablation therapies designed to address prostate conditions, uterine fibroi...
How the Company Makes Money
Profound Medical primarily makes money by selling its capital equipment platform (the TULSA-PRO system) to hospitals and healthcare centers, and by generating recurring revenue from disposable and procedure-related consumables used each time a treatm...
Profound Medical Earnings Call Summary
The call conveyed strong commercial and clinical momentum: improving revenue trends (when adjusted for a one-time shipment timing shift), high gross margins, declining operating expenses, a growing $70M qualified sales pipeline, expanding payer coverage (Q1+Q2 added ~26.8M covered lives and Medicare tailwinds), and compelling randomized clinical evidence (CAPTAIN) that differentiates TULSA on quality-of-life outcomes. Challenges include a $3.1M revenue recognition timing slip, short-term utilization dips at a few sites during model transitions, installation/logistics lags, a proposed ASC reimbursement reduction to monitor, and continued net losses though improving. On balance, the positives — notably the sizable pipeline, reimbursement tailwinds, high margins, and strengthening clinical data — materially outweigh the operational and timing headwinds.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
The company reiterated full‑year 2026 revenue guidance of approximately $25.0M (≈56% growth vs. 2025) and expects full‑year gross margin to remain at 70%+; Q2 revenue was $2.5M (recurring $1.6M; capital $0.871M), up 12% YoY (but would have been ≈$5.6M, +153% YoY, excluding a $3.1M shipment timing shift), Q2 gross margin ~78% (vs. ~73% prior year), total operating expenses $13.0M (down 16% from $15.4M), net loss $9.5M or $0.26/share (vs. ~$15.7M or $0.52/share), and cash of $38.3M at June 30, 2026; installs totaled 84 TULSA PRO systems at quarter end, the qualified sales pipeline is ≈$70M (≈90% TULSA/10% Sonalleve; ~70% U.S./30% international), Index‑20 utilization was -12% sequential but +39% H1‑2026 vs H1‑2025 (+22% YoY), July set a monthly orders record and SRS generated ~160 qualified leads, coverage expanded by ~18.3M lives in Q2 (≈8.5M in Q1; ~30M total covered lives excluding Medicare), and CMS’s proposed 2027 OPPS would pay $15.5K/procedure for TULSA (+14.9%), versus $10.8K for HIFU and $12.3K for Aquablation (TULSA +44% vs HIFU/Aquablation; +26% or ~$3.19K vs robotic RP); ASC proposed payment is $6.87K and physician payment ~$880 for TULSA (vs $865 HIFU, $1,060 robotic RP, $539 Aquablation).
Profound Medical Financial Statement Overview
Summary
Strong and accelerating revenue growth and healthy ~72% TTM gross margin are notable positives, supported by modest leverage (debt-to-equity ~0.15). However, the overall financial profile is still weighed down by very large losses (net margin ~-171% TTM) and heavy, worsening cash burn (operating cash flow and free cash flow around -$35.6M to -$35.8M TTM), indicating ongoing dependence on external funding until costs scale.
Income Statement
34NegativeBalance Sheet
58NeutralCash Flow
27Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 18.97M | 16.38M | 10.68M | 7.20M | 6.68M | 6.87M |
| Gross Profit | 13.61M | 11.59M | 7.04M | 4.38M | 3.02M | 2.95M |
| EBITDA | -33.43M | -41.41M | -32.13M | -27.00M | -26.60M | -28.65M |
| Net Income | -32.42M | -43.32M | -27.82M | -28.57M | -28.67M | -30.70M |
Balance Sheet | ||||||
| Total Assets | 62.28M | 140.62M | 70.23M | 43.91M | 64.42M | 86.78M |
| Cash, Cash Equivalents and Short-Term Investments | 38.21M | 59.61M | 54.91M | 26.21M | 46.52M | 67.15M |
| Total Debt | 7.37M | 4.70M | 5.12M | 7.87M | 8.30M | 1.38M |
| Total Liabilities | 12.56M | 74.30M | 9.81M | 12.73M | 12.42M | 6.16M |
| Stockholders Equity | 49.73M | 66.31M | 60.42M | 31.18M | 52.00M | 80.62M |
Cash Flow | ||||||
| Free Cash Flow | -35.79M | -39.05M | -23.45M | -22.61M | -25.80M | -22.95M |
| Operating Cash Flow | -35.61M | -38.88M | -23.45M | -22.61M | -25.80M | -22.36M |
| Investing Cash Flow | -246.24K | -246.24K | 0 | 0 | 0 | -583.04K |
| Financing Cash Flow | 41.43M | 41.86M | 54.70M | 1.76M | 7.03M | 5.95M |
Profound Medical Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:PRN, the sentiment is Positive. The current price of 9.18 is above the 20-day moving average (MA) of 8.60, above the 50-day MA of 8.72, and below the 200-day MA of 9.26, indicating a neutral trend. The MACD of -0.12 indicates Negative momentum. The RSI at 58.60 is Neutral, neither overbought nor oversold. The STOCH value of 53.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:PRN.
Profound Medical Risk Analysis
Profound Medical disclosed 68 risk factors in its most recent earnings report. Profound Medical reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
0 New RisksProfound Medical Peers Comparison
Overall Rating
- TSE:PRN50Neutral
TSE:ASG47Neutral
TSE:VPT46Neutral
TSE:TLT41.2Neutral
TSE:PINK38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| TSE:PRN | 50Neutral | CAD 335.37M | -6.77 | -62.45% | ― | 59.60% | 32.53% |
| TSE:ASG | 47Neutral | CAD 8.98M | -5.36 | -34.32% | ― | -5.42% | -5.37% |
| TSE:VPT | 46Neutral | CAD 15.43M | -6.13 | 56.40% | ― | 89.06% | 37.62% |
| TSE:TLT | 41Neutral | CAD 55.89M | -12.68 | -130.04% | ― | -24.86% | 18.29% |
| TSE:PINK | 38Underperform | CAD 27.62M | -1.41 | -303.05% | ― | 35.27% | 58.34% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:PRN | Profound Medical | 9.18 | 0.91 | 11.00% | |
| TSE:ASG | Aurora Spine | 0.12 | -0.17 | -58.93% | |
| TSE:PINK | Perimeter Medical Imaging Ai Inc | 0.18 | -0.05 | -23.40% | |
| TSE:TLT | Theralase Technologies | 0.18 | -0.02 | -10.00% | |
| TSE:VPT | VentriPoint Diagnostics | 0.08 | -0.02 | -20.00% |
Profound Medical Corporate Events
Profound Medical Taps Cook iMRI Partnership to Expand TULSA-PRO Reach in U.S.
PositiveProfound Medical has signed a U.S. supply and distribution agreement with Cook Medical’s iMRI Division to add its TULSA-PRO prostate ablation system to Cook’s Copernicus program and iMRI Suite offering. The deal creates a new capital equi...
Profound Medical Enlists Montel Williams to Amplify Prostate Care Advocacy
PositiveProfound Medical is expanding its patient advocacy initiative, Let’s Huddle, by featuring Emmy Award-winning television host and health advocate Montel Williams in a November 5 webinar. The program, led by Global Patient Ambassador Leonard Whee...
Profound Medical, Telix Join Forces to Advance PSMA-Guided Prostate Care
PositiveProfound Medical has entered into a co-education agreement with Telix Pharmaceuticals to jointly educate urologists, radiologists, nuclear medicine physicians and prostate cancer centers on integrating PSMA-PET imaging with MRI-guided TULSA-PRO thera...
Profound Medical Forecasts Record Q3 Revenue, Far Exceeds Street Estimates
PositiveProfound Medical expects to report record preliminary third-quarter 2026 revenue of between $9.8 million and $10.0 million, far ahead of Wall Street forecasts. The company estimates year-over-year growth of roughly 85% to 89% and a sequential jump of...
Profound Medical Taps Industry Veteran Richard Fabian as President in Leadership Realignment
PositiveProfound Medical has appointed industry veteran Richard Fabian as president, reinforcing its executive bench as it scales its interventional MRI-based platforms in prostate care and non-invasive oncology applications. Fabian, a former CEO of FUJIFILM...
Profound Medical Names Industry Veteran Richard Fabian as President in Leadership Realignment
PositiveProfound Medical has appointed veteran healthcare executive Richard Fabian as its new President, while former President Mathieu Burtnyk transitions to the newly created role of Chief Technology Officer. Fabian brings nearly three decades of experienc...
Profound Medical Boosts Orders, Narrows Loss as TULSA Adoption and Coverage Expand
PositiveProfound Medical reported second-quarter 2026 results marked by strong order intake, high margins and tighter cost control, even as some revenue was pushed into early third quarter due to shipment timing. New purchase orders exceeded $7.0 million, wi...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 09, 2026